1428652-17-8CCC(=O)N[C@@H]1CCCc2c(-c3ccc4c(c3)CCC(=O)N4C)cncc21VDEUDSRUMNAXJG-LJQANCHMSA-NBaxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension).
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P264, P270, P280, P301+P317, P318, P319, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
C - Cardiovascular system
QC - Cardiovascular system
VerwendenBaxdrostat is a novel aldosterone synthase Inhibitor for treatment resistant hypertension and systemic Hypertension.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
1428652-17-8DTXSID701358954CHEMBL4113975